Interestingly, our study revealed a cell-specific reduction in FGFBP1 levels in lymphoma cells upon B4 treatment, with negligible effects on FGF signaling molecules like FGF1, FGF2, FGF3, FGF7, FGF10, FGF22, FGFR2, HSPG2, PROM1, and TBX21. The gene discussed is PROM1; the disease is lymphoma.